IN2014MU00916A - - Google Patents

Info

Publication number
IN2014MU00916A
IN2014MU00916A IN916MU2014A IN2014MU00916A IN 2014MU00916 A IN2014MU00916 A IN 2014MU00916A IN 916MU2014 A IN916MU2014 A IN 916MU2014A IN 2014MU00916 A IN2014MU00916 A IN 2014MU00916A
Authority
IN
India
Prior art keywords
pharmaceutical composition
relates
dolutegravir
preparing
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN916MU2014 priority Critical patent/IN2014MU00916A/en
Priority to PCT/GB2015/050826 priority patent/WO2015140569A1/en
Publication of IN2014MU00916A publication Critical patent/IN2014MU00916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN916MU2014 2014-03-20 2015-03-20 IN2014MU00916A (h)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN916MU2014 IN2014MU00916A (h) 2014-03-20 2015-03-20
PCT/GB2015/050826 WO2015140569A1 (en) 2014-03-20 2015-03-20 Pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN916MU2014 IN2014MU00916A (h) 2014-03-20 2015-03-20

Publications (1)

Publication Number Publication Date
IN2014MU00916A true IN2014MU00916A (h) 2015-09-25

Family

ID=54143803

Family Applications (1)

Application Number Title Priority Date Filing Date
IN916MU2014 IN2014MU00916A (h) 2014-03-20 2015-03-20

Country Status (2)

Country Link
IN (1) IN2014MU00916A (h)
WO (1) WO2015140569A1 (h)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7287906B2 (ja) * 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療
GB202009684D0 (en) * 2020-06-26 2020-08-12 Viiv Healthcare Co Formulations
US20230310442A1 (en) * 2020-08-28 2023-10-05 Varalakshmi Mummidi Poly hydroxy oligomer coated dolutegravir aquasomes and method thereof
CN114209655B (zh) * 2021-12-31 2023-11-28 瑞孚信江苏药业股份有限公司 度鲁特韦微粉制备方法
CN114191404B (zh) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 一种多替拉韦片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3284520B1 (en) 2005-04-28 2019-06-05 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
EP2932970B1 (en) 2010-01-27 2018-03-21 VIIV Healthcare Company Antiviral therapy
WO2011131943A2 (en) * 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical compositions
MX2013002802A (es) * 2010-09-13 2013-06-03 Cipla Ltd Composicion farmaceutica.
CN103209687A (zh) * 2010-10-01 2013-07-17 希普拉有限公司 包含地拉罗司的药物组合物
EP2742051B1 (en) * 2011-09-14 2016-10-12 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
CN104884063A (zh) * 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物

Also Published As

Publication number Publication date
WO2015140569A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
ZA201708692B (en) Antibacterial compounds
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
GB2541571A (en) Pharmaceutical compositions
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
CL2015002897A1 (es) Inhibidores de bace1
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
IN2014MU00303A (h)
EP4218736A3 (en) Compositions comprising 15-hepe
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12017500602A1 (en) Methods for treating ocular conditions
IN2014MU00916A (h)
IN2014CH00840A (h)
FI20165932A7 (fi) Immunomodulatorisia koostumuksia
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase
PT3394069T (pt) Processo para a preparação de inibidores de integrase de vih
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
IN2014MU00495A (h)